Hospital
ST. Joseph Health Northern California, LLC
ST. Joseph Health Northern California, LLC was paid $22.34M by Medicaid between Feb 2018 and Nov 2024, across 204 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 12% of everything it billed.
33Billing provider infoST. JOSEPH HEALTH NORTHERN CALIFORNIA, LLC
NAPA, CA 94558
NAPA, CA 94558
33aNPI1235218785assigned 11/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.34M
24GClaims484,843
24DCodes billed204
24AFirst – last monthFeb 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#114 of 410
Median peer was paid$6.90M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 675 | $13K | |
| 2019 | 62,330 | $2.68M | |
| 2020 | 67,540 | $2.90M | |
| 2021 | 80,303 | $3.35M | |
| 2022 | 91,600 | $4.09M | |
| 2023 | 100,837 | $4.77M | |
| 2024incomplete | 81,558 | $4.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 12% | 33,781 | 28,681 | $2.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 36,326 | 30,083 | $2.56M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.7% | 55,658 | 11,882 | $2.16M |
| G9012 | Other specified case management service not elsewhere classified | 5.8% | 3,562 | 3,318 | $1.29M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 2,708 | 2,602 | $909K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.9% | 10,468 | 8,893 | $865K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.8% | 3,975 | 3,884 | $623K |
| 97750 | 2.8% | 8,385 | 5,061 | $617K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 6,956 | 6,154 | $565K |
| 97139 | 2.4% | 14,176 | 2,865 | $546K | |
| J3490 | Unclassified drugs | 2.4% | 39,520 | 18,283 | $529K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 6,882 | 5,518 | $408K |
192 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 4,935 | $407K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,050 | $393K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 8,283 | $327K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.4% | 1,025 | $307K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 1,769 | $261K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,282 | $256K |
| 97010 | 1.1% | 7,429 | $253K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 742 | $248K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,028 | $240K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,696 | $185K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,649 | $180K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 801 | $175K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,489 | $173K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,511 | $172K |
| 59025 | Fetal non-stress test | <1% | 4,573 | $166K |
| 0450 | Emergency room services | <1% | 950 | $164K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 447 | $163K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 249 | $160K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,251 | $158K |
| 99201 | <1% | 2,557 | $156K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,237 | $156K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,997 | $154K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,205 | $152K |
| 76830 | Ultrasound, transvaginal | <1% | 1,365 | $151K |
| 87631 | <1% | 2,374 | $145K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,930 | $140K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,476 | $135K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,161 | $123K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,417 | $120K |
| 97802 | <1% | 834 | $95K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,329 | $93K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,058 | $88K |
| 99070 | <1% | 3,024 | $86K | |
| 76770 | <1% | 893 | $85K | |
| Z7502 | <1% | 1,924 | $72K | |
| 97799 | <1% | 2,234 | $70K | |
| 97803 | <1% | 1,078 | $63K | |
| 97165 | <1% | 968 | $61K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 182 | $60K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,210 | $59K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 793 | $57K |
| 73030 | <1% | 1,321 | $56K | |
| 72100 | <1% | 1,147 | $50K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,721 | $49K |
| 84484 | <1% | 5,043 | $48K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,044 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,531 | $46K |
| 73630 | <1% | 1,262 | $44K | |
| 83690 | <1% | 6,202 | $42K | |
| 83880 | <1% | 1,471 | $41K | |
| 77065 | Tomosynthesis, mammo | <1% | 269 | $40K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 844 | $39K |
| 76536 | <1% | 413 | $38K | |
| 73610 | <1% | 977 | $37K | |
| 93971 | <1% | 241 | $36K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,171 | $36K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 636 | $34K |
| 73130 | <1% | 914 | $33K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,197 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,571 | $33K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,148 | $32K |
| 83605 | <1% | 2,780 | $30K | |
| 99285 | Emergency room visit (most serious) | <1% | 13 | $30K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,657 | $30K |
| 73560 | <1% | 1,134 | $30K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 181 | $29K |
| 76642 | <1% | 304 | $27K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,927 | $25K |
| 88342 | <1% | 1,280 | $25K | |
| 83735 | <1% | 3,659 | $25K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,153 | $24K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 518 | $24K |
| 73110 | <1% | 619 | $24K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,669 | $23K |
| 87040 | <1% | 2,240 | $23K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 71 | $23K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 512 | $23K |
| 81001 | <1% | 4,686 | $22K | |
| 73221 | <1% | 54 | $22K | |
| 72141 | <1% | 62 | $22K | |
| 84145 | <1% | 1,033 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,776 | $19K |
| 76641 | <1% | 205 | $18K | |
| 88313 | <1% | 1,087 | $18K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,704 | $18K |
| 81025 | <1% | 4,421 | $17K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,911 | $16K |
| 90715 | <1% | 352 | $16K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 46 | $15K |
| 82947 | <1% | 2,952 | $15K | |
| 74018 | <1% | 538 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,598 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,535 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 38 | $13K |
| 87077 | <1% | 1,650 | $13K | |
| 97164 | <1% | 219 | $12K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,122 | $12K |
| 81003 | <1% | 5,311 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 764 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 306 | $11K |
| 0353U | <1% | 191 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,584 | $10K |
| 85610 | <1% | 2,711 | $10K | |
| 87081 | <1% | 1,514 | $10K | |
| Z9725 | <1% | 227 | $10K | |
| 70498 | <1% | 31 | $9K | |
| 99152 | <1% | 158 | $9K | |
| 70496 | <1% | 30 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,369 | $9K |
| 87186 | <1% | 1,117 | $8K | |
| 73502 | <1% | 193 | $8K | |
| 72050 | <1% | 101 | $8K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 211 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 548 | $7K |
| 73562 | <1% | 198 | $7K | |
| 73140 | <1% | 201 | $6K | |
| 70486 | <1% | 26 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 28 | $6K |
| 76870 | <1% | 53 | $5K | |
| 87070 | <1% | 846 | $5K | |
| 85379 | <1% | 567 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 183 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 182 | $5K |
| 71250 | <1% | 29 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 63 | $4K |
| 72170 | <1% | 121 | $4K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 76 | $4K |
| 96367 | <1% | 65 | $4K | |
| 77080 | <1% | 72 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 689 | $3K |
| 82077 | <1% | 136 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $3K |
| 85027 | <1% | 427 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 437 | $3K |
| 92522 | <1% | 15 | $3K | |
| 93970 | <1% | 12 | $3K | |
| 76801 | <1% | 24 | $3K | |
| 80047 | <1% | 283 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 122 | $2K |
| 86901 | <1% | 916 | $2K | |
| 86900 | <1% | 900 | $2K | |
| 87641 | <1% | 56 | $2K | |
| 85730 | <1% | 334 | $2K | |
| 73080 | <1% | 55 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 237 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 218 | $2K |
| 86140 | <1% | 348 | $2K | |
| 93017 | <1% | 12 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 227 | $1K |
| 87205 | <1% | 491 | $1K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 14 | $1K |
| 10060 | <1% | 36 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 127 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 27 | $1K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 21 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 100 | $991.51 |
| 12001 | <1% | 27 | $969.73 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 214 | $933.20 |
| 81002 | <1% | 503 | $917.22 | |
| 86850 | <1% | 326 | $872.50 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 61 | $845.07 |
| 87420 | <1% | 332 | $784.32 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 30 | $764.75 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 103 | $763.78 |
| 36415 | Collection of venous blood by venipuncture | <1% | 65 | $752.16 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 85 | $666.84 |
| 72040 | <1% | 12 | $656.20 | |
| 87075 | <1% | 81 | $597.56 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 56 | $516.91 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 88 | $490.77 |
| Z7610 | <1% | 119 | $390.42 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $376.14 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $331.38 |
| 88304 | <1% | 50 | $305.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 58 | $293.48 |
| 82248 | <1% | 50 | $258.04 | |
| 80061 | Lipid panel | <1% | 28 | $237.05 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 21 | $234.49 |
| 82550 | <1% | 28 | $164.86 | |
| 82803 | <1% | 14 | $146.94 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $145.50 |
| 29125 | <1% | 13 | $140.13 | |
| 82140 | <1% | 15 | $139.80 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 17 | $101.87 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $95.34 |
| 84100 | <1% | 21 | $74.22 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $66.90 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 87 | $28.13 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 114 | $4.18 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 57 | $4.09 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 31 | $3.68 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 20 | $0.19 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Parent organizationST. JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.